3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
58
Carcinoma, Non-Small-Cell Lung
36
Urinary Bladder Neoplasms
33
Neoplasm Metastasis
20
Lung Neoplasms
20
Ovarian Neoplasms
19
Lymphoma, Large B-Cell, Diffuse
18
Cholangiocarcinoma
15
Neoplasms
14
Nasopharyngeal Carcinoma
14
Biliary Tract Neoplasms
14
Triple Negative Breast Neoplasms
13
Colorectal Neoplasms
12
Breast Neoplasms
12
Carcinoma, Transitional Cell
11
Non-Muscle Invasive Bladder Neoplasms
10
Fallopian Tube Neoplasms
10
Recurrence
9
Gallbladder Neoplasms
8
Sarcoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Bile Duct Neoplasms
6
Uterine Cervical Neoplasms
5
Osteosarcoma
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Hodgkin Disease
5
Endometrial Neoplasms
5
Melanoma
4
Gastrointestinal Neoplasms
4
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Urothelial Cancer
×
Gemcitabine
×
90 days
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA